Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-536 in Low or Intermediate-1 Risk MDS-Related Anemia
DRKS00004531Phase 2Recruiting
- Sponsor
- Acceleron Pharma Inc.
- Start
- Feb 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of luspatercept in myelodysplastic syndrome (MDS) and anaemia (8 arms), sponsored by Acceleron Pharma Inc. Started Feb 2013; status: recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on DRKS00004531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004531.